TD Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $70.3M | Sell |
233,696
-48,152
| -17% | -$14.5M | 0.06% | 240 |
|
|
2026
Q1 | $93.3M | Buy |
281,848
+12,747
| +5% | +$4.34M | 0.08% | 204 |
|
|
2025
Q4 | $107M | Sell |
269,101
-43,416
| -14% | -$19.2M | 0.09% | 186 |
|
|
2025
Q3 | $143M | Sell |
312,517
-128,660
| -29% | -$52.4M | 0.12% | 157 |
|
|
2025
Q2 | $144M | Sell |
441,177
-45,407
| -9% | -$12.6M | 0.12% | 150 |
|
|
2025
Q1 | $131M | Sell |
486,584
-17,454
| -3% | -$4.49M | 0.12% | 156 |
|
|
2024
Q4 | $119M | Buy |
504,038
+15,755
| +3% | +$4.14M | 0.1% | 175 |
|
|
2024
Q3 | $134M | Sell |
488,283
-1,657
| -0.3% | -$431K | 0.12% | 167 |
|
|
2024
Q2 | $119M | Buy |
489,940
+27,592
| +6% | +$4.36M | 0.11% | 169 |
|
|
2024
Q1 | $69.1M | Sell |
462,348
-3,737
| -0.8% | -$623K | 0.06% | 254 |
|
|
2023
Q4 | $89.2M | Sell |
466,085
-29,279
| -6% | -$4.99M | 0.09% | 202 |
|
|
2023
Q3 | $87.7M | Buy |
495,364
+136,283
| +38% | +$26M | 0.11% | 157 |
|
|
2023
Q2 | $68.2M | Sell |
359,081
-783
| -0.2% | -$155K | 0.08% | 203 |
|
|
2023
Q1 | $72.1M | Sell |
359,864
-32,586
| -8% | -$6.85M | 0.09% | 183 |
|
|
2022
Q4 | $93.3M | Buy |
392,450
+7,639
| +2% | +$1.63M | 0.12% | 150 |
|
|
2022
Q3 | $80.6M | Sell |
384,811
-15,457
| -4% | -$2.95M | 0.1% | 161 |
|
|
2022
Q2 | $58.4M | Buy |
400,268
+7,586
| +2% | +$1.08M | 0.07% | 227 |
|
|
2022
Q1 | $64.1M | Sell |
392,682
-3,791
| -1% | -$578K | 0.06% | 246 |
|
|
2021
Q4 | $67.2M | Buy |
396,473
+161,789
| +69% | +$30.1M | 0.06% | 256 |
|
|
2021
Q3 | $44.3M | Buy |
234,684
+10,584
| +5% | +$1.99M | 0.05% | 304 |
|
|
2021
Q2 | $40.1M | Buy |
224,100
+32,078
| +17% | +$4.7M | 0.04% | 338 |
|
|
2021
Q1 | $27.1M | Buy |
192,022
+16,495
| +9% | +$2.48M | 0.03% | 399 |
|
|
2020
Q4 | $22.8M | Buy |
175,527
+8,080
| +5% | +$1.08M | 0.03% | 416 |
|
|
2020
Q3 | $24.4M | Buy |
167,447
+9,887
| +6% | +$1.41M | 0.03% | 349 |
|
|
2020
Q2 | $23.3M | Buy |
157,560
+8,743
| +6% | +$1.18M | 0.03% | 331 |
|
|
2020
Q1 | $16.2M | Buy |
148,817
+16,600
| +13% | +$1.92M | 0.03% | 364 |
|
|
2019
Q4 | $15.2M | Buy |
132,217
+18,165
| +16% | +$1.81M | 0.02% | 444 |
|
|
2019
Q3 | $9.17M | Buy |
114,052
+17,800
| +18% | +$1.41M | 0.01% | 544 |
|
|
2019
Q2 | $6.98M | Buy |
96,252
+3,730
| +4% | +$286K | 0.01% | 610 |
|
|
2019
Q1 | $8.65M | Sell |
92,522
-1,185
| -1% | -$99.1K | 0.01% | 557 |
|
|
2018
Q4 | $6.83M | Sell |
93,707
-13,331
| -12% | -$1.03M | 0.01% | 579 |
|
|
2018
Q3 | $9.37M | Sell |
107,038
-19,250
| -15% | -$1.94M | 0.01% | 551 |
|
|
2018
Q2 | $12.4M | Sell |
126,288
-42,608
| -25% | -$4.23M | 0.02% | 476 |
|
|
2018
Q1 | $20.1M | Buy |
168,896
+9,950
| +6% | +$1.28M | 0.03% | 378 |
|
|
2017
Q4 | $20.2M | Buy |
158,946
+20,151
| +15% | +$2.53M | 0.03% | 388 |
|
|
2017
Q3 | $16.3M | Buy |
138,795
+8,877
| +7% | +$758K | 0.02% | 432 |
|
|
2017
Q2 | $10.4M | Buy |
129,918
+34,918
| +37% | +$2.23M | 0.02% | 514 |
|
|
2017
Q1 | $4.87M | Buy |
95,000
+2,200
| +2% | +$102K | 0.01% | 695 |
|
|
2016
Q4 | $3.47M | Buy |
92,800
+3,262
| +4% | +$137K | 0.01% | 754 |
|
|
2016
Q3 | $6.07M | Buy |
89,538
+258
| +0.3% | +$18.2K | 0.01% | 653 |
|
|
2016
Q2 | $4.95M | Buy |
89,280
+65,680
| +278% | +$4.14M | 0.01% | 679 |
|
|
2016
Q1 | $1.48M | Buy |
23,600
+2,300
| +11% | +$153K | ﹤0.01% | 887 |
|
|
2015
Q4 | $2M | Buy |
21,300
+2,200
| +12% | +$204K | ﹤0.01% | 833 |
|
|
2015
Q3 | $1.53M | Buy |
19,100
+1,000
| +6% | +$111K | ﹤0.01% | 858 |
|
|
2015
Q2 | $2.17M | Buy |
18,100
+3,100
| +21% | +$370K | ﹤0.01% | 844 |
|
|
2015
Q1 | $1.57M | Hold |
15,000
| – | – | ﹤0.01% | 866 |
|
|
2014
Q4 | $1.46M | Sell |
15,000
-28,100
| -65% | -$2.6M | ﹤0.01% | 879 |
|
|
2014
Q3 | $3.37M | Buy |
43,100
+300
| +0.7% | +$19.4K | 0.01% | 731 |
|
|
2014
Q2 | $2.7M | Sell |
42,800
-12,800
| -23% | -$761K | ﹤0.01% | 785 |
|
|
2014
Q1 | $3.73M | Sell |
55,600
-5,400
| -9% | -$418K | 0.01% | 722 |
|
|
2013
Q4 | $3.92M | Sell |
61,000
-9,700
| -14% | -$579K | 0.01% | 700 |
|
|
2013
Q3 | $4.53M | Buy |
70,700
+25,700
| +57% | +$1.28M | 0.01% | 632 |
|
|
2013
Q2 | $1.4M | Buy |
+45,000
| New | +$1.2M | ﹤0.01% | 809 |
|
Other funds holding ALNY
VPM
VCM
TD Asset Management's ALNY Position: Q2 2026 in Review
TD Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 17% in Q2 2026, selling an estimated $14.5M and leaving 233,696 shares worth $70.3M. The position accounts for 0.06% of the portfolio, ranked #240.
TD Asset Management first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $144M in Q2 2025. 587 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.
- TD Asset Management held 233,696 shares of Alnylam Pharmaceuticals worth $70.3M as of Q2 2026.
- TD Asset Management sold 48,152 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $14.5M.
- Alnylam Pharmaceuticals made up 0.06% of TD Asset Management's portfolio in Q2 2026, its #240 holding.
- TD Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- TD Asset Management's Alnylam Pharmaceuticals position peaked at $144M in Q2 2025.
- 587 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.
Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.